Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand (TRAIL) ...

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand with ...

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

2. Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/ ...

On-demand video webcast now available here HOUSTON, TX / ACCESSWIRE / 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a bi ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

PSA doubling time is an essential criterion for high-risk biochemically recurrent prostate cancer that should prompt treatment escalation.

OPTYX study shows many patients with advanced prostate cancer preferred oral relugolix over injectables for androgen deprivation therapy.

Pfizer’s Talzenna in combi with Xtandi improves survival outcomes in metastatic castration resistant prostate cancer: New York Saturday, February 15, 2025, 11:00 Hrs [IST] Pfize ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...